Clinical Trials · NCT05050084

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Name: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Active Not Recruiting
Sponsor: NRG Oncology
Enrollment: 2,050
Start date: Dec 2021
Locations: 576 sites, United States, Canada
Primary endpoint: Distant metastasis (DM) (De-intensification study)

View Gonadorelin compound reference